<DOC>
	<DOC>NCT02858362</DOC>
	<brief_summary>A Phase 2 Clinical Study to Assess the Activity and Safety of Utrophin Modulation with SMT C1100 (ezutromid) in Ambulatory Paediatric Male Subjects with Duchenne Muscular Dystrophy (DMD)</brief_summary>
	<brief_title>PoC Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With DMD</brief_title>
	<detailed_description>This is a Phase 2, open-label, study to assess the activity and safety of utrophin modulation with SMT C1100 (ezutromid) 2500 mg administered orally bid in ambulatory paediatric male subjects with DMD. Approximately 40 subjects with DMD will be enrolled in this study. This study will be conducted in a multi-centre setting in both the United Kingdom and the United States of America and comprises of a Screening and Baseline Phase of up to 28 days, a 48-week open label Treatment Phase and a 30-day Safety Follow up Phase.</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
	<criteria>Male Age â‰¥5 and &lt;10 years (from 5th birthday to 10th birthday) DMD diagnosis Willing and able to comply with study procedures, including 2 muscle biopsy procedures Able to undergo MRI Have used at least 6 months stable dose systemic corticosteroids Ability to walk 300 metres unassisted and below 80% predicted 6MWD Uncontrolled congestive heart failure (CHF) or recent change in CHF prophylaxis/treatment Use of beta blockers, herbal supplements, BCRP substrates, SNRIs, SSRIs, tricyclic antidepressants, or ADHD treatments such as methylphenidate or PEA. Use of over the counter, herbal or prescription CYP2B6, CYP1A1 or CYP1A2 inhibitors, inducers or substrates. Exposure to other investigational drug or DMD interventional agent within 3 months (except FORDMD Study participants are permitted) Require daytime ventilator assistance Be dairy or lactose intolerant Be a smoker, use other tobacco or nicotine products or be exposed to daily passive smoking Use of an approved DMD medication or anticipate use during the study (other than steroids)</criteria>
	<gender>Male</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>DMD</keyword>
	<keyword>Muscular Dystrophy</keyword>
	<keyword>Utrophin</keyword>
	<keyword>Duchenne</keyword>
	<keyword>PhaseOut DMD</keyword>
</DOC>